Executive Summary
FDA's 28 Apr 2025—A Texas federal court ruled in favor of Novo Nordisk andFDA, denying acompoundingtrade association's motion to freeze theFDA'sdecision to end the shortage
A legal battle has erupted between drug compounders and the U.S. Food and Drug Administration (FDA) following the agency's recent declaration that the shortage of semaglutide, the active ingredient in popular medications like Ozempic and Wegovy, has been resolved. This decision has led to a lawsuit filed by an association representing compounders against the FDA, alleging that the agency's move was "reckless and arbitrary" and will negatively impact patients.
The core of the dispute lies in the FDA's decision on February 21, 2025, to remove semaglutide from its official drug shortage list. This action effectively signals the end to the recognized scarcity of the drug, which had previously allowed compounding pharmacies to produce and distribute their own versions of semaglutide-based treatments. While the FDA stated that the supply now meets or exceeds current and projected U.S. demands, compounders argue this declaration will "deprive patients of a vital treatment for type 2 diabetes, obesity, cardiovascular" conditions.
Compounders sued the FDA and the agency's decision has triggered multiple legal actions. One such lawsuit was filed by the Outsourcing Facility Association (OFA), which described the FDA's move as a benefit to "special interests" and a means to "raise drug prices and deprive much of the public access to a needed medicine." The OFA contends that the semaglutide drug shortage has been resolved prematurely and that this will hinder access to crucial medications for many individuals.
The FDA's stance is that with the shortages officially over, compounding pharmacies will have a grace period of 60 to 90 days before facing enforcement action. However, the lawsuit seeks to keep the drug on the shortage list and allow for the continued compounding of semaglutide until litigation concludes. On February 24, 2025, this lawsuit was filed, with compounders arguing that the FDA overstepped its authority.
This is not the first time compounders have sued the FDA over such decisions. In fact, the same compounding trade group previously sued the FDA over the resolution of the shortage for tirzepatide, another GLP-1 receptor agonist. The recent legal action highlights ongoing tension between approved drug manufacturers and compounding pharmacies, particularly concerning high-demand medications.
Novo Nordisk, the manufacturer of Ozempic and Wegovy, has also become involved in the legal proceedings, intervening in some lawsuits. A Texas federal court recently ruled in favor of Novo Nordisk and the FDA, denying a compounding trade association's motion to halt the FDA's decision to end the shortage. This ruling has implications for the ability of compounding pharmacies to continue producing their versions of semaglutide.
The FDA's guidance clarifies that under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, drug compounders must soon cease compounding semaglutide injection products. The FDA declares end to Novo Nordisk's semaglutide shortage directive means that from April 22, 2025, and potentially extending to May 22, depending on specific authorizations, compounding pharmacies will be required to stop offering their semaglutide products.
The controversy underscores the complex regulatory landscape surrounding drug shortages and the role of compounding pharmacies in addressing them. While the FDA aims to ensure the availability of approved medications, compounders argue they play a vital role in providing accessible and sometimes more affordable alternatives, especially during periods of scarcity. The ongoing legal battles will likely shape future policies regarding drug availability and compounding practices. The semaglutide lawsuit and related legal actions are ongoing, with further court decisions anticipated.
Related Articles
Frequently Asked Questions
Here are the most common questions about .
Leave a Comment
Share your thoughts, feedback, or additional insights on this topic.
